Tesmilifene is a small molecule chemopotentiator. In the first Phase III trial which enrolled 305 women overall survival in women on the combination of tesmilifene with anthracycline (the standard of care in metastatic breast cancer) was greater than 50% longer than for women treated with the standard of care alone. The drug has been clinically demonstrated to increase the effectiveness of the current principal chemotherapeutic drugs anthracyclines and taxanes which are used in the majority of cancers.
http://www.stockhouse.ca/news/news.a...newsid=2222151